TearLab Corp fka TEAR

[Wildbilly]

In conversation with Elias Vamvakas
January 28, 2014 by leonardzehr ·

Elias Vamvakas
As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nanoliters of tear fluid in order to measure tear osmolarity, and objectively diagnose DED. TearLab’s technology eliminates the challenges that previously prevented point-of-care osmolarity testing and can produce a sample-to-answer result in less than 30 seconds. Prior to his involvement with TearLab, Mr. Vamvakas was a co-founder of TLC Vision, which pioneered LASIK laser eye surgery in the U.S. In this interview with BioTuesdays.com, Mr. Vamvakas reflects on the first six quarters of TearLab’s commercial roll out.

FULL ARTICLE:

http://biotuesdays.com/2014/01/28/in-conversation-with-elias-vamvakas/